Association for Behavior Analysis International

The Association for Behavior Analysis International® (ABAI) is a nonprofit membership organization with the mission to contribute to the well-being of society by developing, enhancing, and supporting the growth and vitality of the science of behavior analysis through research, education, and practice.


36th Annual Convention; San Antonio, TX; 2010

Workshop Details

Previous Page


Workshop #W39
CE Offered: BACB
Integrating Applied Behavior Analysis With Psychiatry: An Interdisciplinary Approach to Medication Management
Friday, May 28, 2010
6:00 PM–9:00 PM
Texas Ballroom Salon C (Grand Hyatt)
Area: AUT; Domain: Applied Behavior Analysis
CE Instructor: Bryan Davey, Ph.D.
LISA A. STUDER (Melmark New England), JAMES CHOK (Melmark New England), SILVA ORCHANIAN (Melmark New England), FRANK L. BIRD (Melmark New England)
Description: This workshop will discuss an interdisciplinary team approach to treating severely challenging behaviors, with a focus on the integration of applied behavior analytic (ABA) services and psychopharmacological intervention. The workshop will begin with an overview of the various classes of psychiatric medications and a review of the available research concerning the effectiveness of medications for individuals with developmental disabilities. Next, the utility of integrating psychopharmacological treatment with ABA services, along with the unique challenges of evaluating medication effects in children with limited communication skills, will be discussed. The critical role data analysis plays in evaluating psychopharmacologic interventions will be highlighted and several case studies will be reviewed that demonstrate a variety of clinical outcomes for students with developmental disabilities receiving psychopharmacologic services at our agency. Lastly, participants will be asked to evaluate hypothetical data of individuals receiving psychiatric medications and make recommendations during a role-playing exercise of an interdisciplinary treatment team review.
Learning Objectives: At the conclusion of this workshop, participants will be able to do the following: 1. identify the major psychiatric medication classes and the main therapeutic function of each class, 2. have a better understanding of the available scientific literature regarding the effectiveness of psychiatric medications with individuals with developmental disabilities, 3. identify the benefits and limitations of combining psychopharmacologic and ABA interventions, 4. analyze behavioral data to aid in the decision making process when psychiatric medication is part of the treatment plan, and 5. effectively communicate key behavioral changes that are associated with the main functions and side effect profiles of major psychiatric medications.
Activities: With the guidance and assistance of workshop presenters, participants will engage in a discussion regarding the different components of the interdisciplinary approach to treating severely challenging behaviors. Individuals will discuss their experiences with this approach and highlight the benefits and limitations. Participants will review sample case data and practice identifying key behavioral changes that may be associated with the introduction of psychiatric medications. Participants will also practice making recommendations from an ABA perspective with an appreciation for the potential impact psychopharmacologic interventions may be having on behavior.
Audience: This workshop is for behavior analysts, behavioral psychologists, professionals in a similar field, and parents and caregivers who work with individuals with significant behavior challenges.
Content Area: Practice
Instruction Level: Basic



Back to Top
Modifed by Eddie Soh